Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'India, China Hold Key to Drug Firms' Global Expansion' (Asia)

This article was originally published in PharmAsia News

Executive Summary

Global pharmaceutical companies will have to expand into China and India to compete in the expanding world pharmaceutical market, concludes the new pharmaceutical report "Pharma 2020" by PricewaterhouseCoopers. Companies need to begin testing drugs with human patients earlier in the developmental process, says Pharma 2020, to avoid failure during expensive late-stage clinical trials. In the year 2020, China will be either the second or third largest pharmaceutical market in the world, predicts the report. In addition, up to 20 percent of all worldwide drugs sales will occur in the developing countries of Brazil, China, India, Indonesia, Mexico, Russia, and Turkey. The report predicts that the global pharmaceutical market will total $1.3 trillion in 2020. The most competitive companies will be focusing on many lower-cost medicines, rather than on billion-dollar blockbuster drugs. (Click here for more

You may also be interested in...



Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

WHO Prequalifies Celltrion’s Rituximab

Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times

26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel